Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

PR Newswire October 28, 2024

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

PR Newswire October 22, 2024

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

PR Newswire October 14, 2024

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

PR Newswire October 1, 2024

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

PR Newswire September 30, 2024

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

PR Newswire September 9, 2024

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire September 5, 2024

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

PR Newswire September 3, 2024

RedHill Biopharma Announces First Half 2024 Business Highlights

PR Newswire August 29, 2024

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

PR Newswire August 26, 2024

Talicia® Launched in the United Arab Emirates

PR Newswire August 21, 2024

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

PR Newswire August 19, 2024

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

PR Newswire August 16, 2024

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

PR Newswire August 1, 2024

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

PR Newswire July 22, 2024

RedHill Biopharma Terminates License Agreement for Aemcolo®

PR Newswire July 9, 2024

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

PR Newswire June 3, 2024

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

PR Newswire May 6, 2024

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

PR Newswire April 24, 2024

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

PR Newswire April 8, 2024